000154800 001__ 154800
000154800 005__ 20240229133504.0
000154800 0247_ $$2doi$$a10.1007/s00259-020-04777-z
000154800 0247_ $$2pmid$$apmid:32405735
000154800 0247_ $$2ISSN$$a0340-6997
000154800 0247_ $$2ISSN$$a1432-105X
000154800 0247_ $$2ISSN$$a1619-7070
000154800 0247_ $$2ISSN$$a1619-7089
000154800 037__ $$aDKFZ-2020-01038
000154800 041__ $$aeng
000154800 082__ $$a610
000154800 1001_ $$aKoerber, Stefan A$$b0
000154800 245__ $$aClinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer.
000154800 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2021
000154800 3367_ $$2DRIVER$$aarticle
000154800 3367_ $$2DataCite$$aOutput Types/Journal article
000154800 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1614947446_29979
000154800 3367_ $$2BibTeX$$aARTICLE
000154800 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000154800 3367_ $$00$$2EndNote$$aJournal Article
000154800 500__ $$a2021 Jan;48(1):143-151
000154800 520__ $$aFirst-line treatment of patients with recurrent, metastatic prostate cancer involves hormone therapy with or without additional systemic therapies. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) allows the detection of oligometastatic disease that may be amenable to image-guided radiotherapy. The current study classifies the type and localization of metastases and the clinical outcome of PSMA-PET/CT-guided radiotherapy to selected metastases.Between 2011 and 2019, 86 patients with recurrent, oligometastatic prostate carcinoma were identified by PSMA-PET/CT and were treated with image-guided radiotherapy of their metastases. Sites of relapse were characterized, and the primary endpoint overall survival (OS), biochemical progression-free survival (bPFS), and androgen deprivation therapy (ADT)-free survival were tabulated.In total, 37% of the metastases were bone metastases, 48% were pelvic nodal metastases, and 15% were nodal metastases outside of the pelvis. After PSMA-guided radiotherapy, a biochemical response was detected in 83% of the cohort. A statistically significant decrease in the standard uptake value (SUV) was seen in irradiated metastases. After a median follow-up of 26 months, the 3-year OS and bPFS were 84% and 55%, respectively. The median time of ADT-free survival was 13.5 months. A better clinical outcome was observed for patients receiving concomitant ADT or more than 24 fractions of radiation.PSMA-guided radiotherapy is a promising therapeutic approach with excellent infield control for men with oligorecurrent prostate carcinoma. However, prospective, randomized trials are necessary to determine if this approach confers a survival advantage.
000154800 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000154800 588__ $$aDataset connected to CrossRef, PubMed,
000154800 7001_ $$aSprute, Katharina$$b1
000154800 7001_ $$aKratochwil, Clemens$$b2
000154800 7001_ $$aWinter, Erik$$b3
000154800 7001_ $$aHaefner, Matthias F$$b4
000154800 7001_ $$aKatayama, Sonja$$b5
000154800 7001_ $$aSchlampp, Ingmar$$b6
000154800 7001_ $$aHerfarth, Klaus$$b7
000154800 7001_ $$0P:(DE-HGF)0$$aKopka, Klaus$$b8
000154800 7001_ $$aAfshar-Oromieh, Ali$$b9
000154800 7001_ $$aZschaebitz, Stefanie$$b10
000154800 7001_ $$0P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aHolland-Letz, Tim$$b11
000154800 7001_ $$aChoyke, Peter L$$b12
000154800 7001_ $$aJaeger, Dirk$$b13
000154800 7001_ $$aHohenfellner, Markus$$b14
000154800 7001_ $$0P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aHaberkorn, Uwe$$b15$$udkfz
000154800 7001_ $$0P:(DE-HGF)0$$aDebus, Juergen$$b16
000154800 7001_ $$0P:(DE-He78)5ca7e97b2769bb97f8c73431c6566b94$$aGiesel, Frederik$$b17$$eLast author$$udkfz
000154800 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-020-04777-z$$n1$$p143-151$$tEuropean journal of nuclear medicine and molecular imaging$$v48$$x1619-7089$$y2021
000154800 909CO $$ooai:inrepo02.dkfz.de:154800$$pVDB
000154800 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000154800 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000154800 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000154800 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000154800 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ca7e97b2769bb97f8c73431c6566b94$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000154800 9130_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000154800 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000154800 9141_ $$y2021
000154800 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000154800 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000154800 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000154800 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000154800 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000154800 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NUCL MED MOL I : 2017
000154800 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000154800 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000154800 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000154800 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000154800 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000154800 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000154800 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NUCL MED MOL I : 2017
000154800 9202_ $$0I:(DE-He78)E060-20160331$$kE060$$lE060 KKE Nuklearmedizin$$x0
000154800 9201_ $$0I:(DE-He78)E030-20160331$$kE030$$lE030 Radiopharmazeutische Chemie$$x0
000154800 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x1
000154800 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000154800 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x3
000154800 9201_ $$0I:(DE-He78)E060-20160331$$kE060$$lE060 KKE Nuklearmedizin$$x4
000154800 980__ $$ajournal
000154800 980__ $$aVDB
000154800 980__ $$aI:(DE-He78)E030-20160331
000154800 980__ $$aI:(DE-He78)C060-20160331
000154800 980__ $$aI:(DE-He78)HD01-20160331
000154800 980__ $$aI:(DE-He78)E050-20160331
000154800 980__ $$aI:(DE-He78)E060-20160331
000154800 980__ $$aUNRESTRICTED